Cardiovascular

India has amongst the highest rates of cardiovascular disease (CVD) globally. As per WHO, cardiovascular diseases contribute to 26% of deaths in India. CVDs can be prevented by controlling one’s blood pressure, keeping cholesterol under control, eating healthy, regular exercise, maintaining proper weight, abstaining from smoking and other lifestyle changes. Medication for treating CVD includes drugs for lowering cholesterol and managing high blood pressure.
Eris remains devoted to providing better healthcare solutions via superior products and patient care initiatives to enable early detection. By advancing awareness and precise screening essential to curb risk factors for various CVDs, it also strives to provide comprehensive care in mitigating and curbing various risk factors. Through its cutting edge screening and monitoring initiatives, Eris is committed to promoting better clinical outcomes for various CVD risk factors.

Cardiac

Key Mother Brand Groups Subgroups
Telmisartan and combinations
Olmesartan and combinations
Cilnidipine and combinations
Rosuvastatin and combinations
Atorvastatin and combinations

New Launches : Ticasave (Ticagrelor)

Key Mother Brand Groups

Molecule

Telmisartan and combinations

Eritel

Molecule

Olmesartan and combinations

Olmin

Molecule

Cilnidipine and combinations

LNBLOC

Molecule

Rosuvastatin and combinations

Crevast

Molecule

Atorvastatin and combinations

Atorsave

NEW LAUNCH

Molecule

Ticagrelor

Ticasave

Copyright © 2021 Eris Lifesciences Limited. All Rights Reserved.